Home/Filings/4/0000899243-23-012901
4//SEC Filing

Nguyen Alexander Hieu 4

Accession 0000899243-23-012901

CIK 0001463361other

Filed

May 11, 8:00 PM ET

Accepted

May 12, 8:04 PM ET

Size

16.1 KB

Accession

0000899243-23-012901

Insider Transaction Report

Form 4
Period: 2023-05-11
Nguyen Alexander Hieu
CLO and Head of Ops
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-05-11$2.77/sh+40,000$110,80040,000 total
    Exercise: $2.77Exp: 2033-05-11Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-05-112,0830 total
    Exercise: $41.80Exp: 2031-06-24Common Stock (2,083 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-05-11+2,0832,083 total
    Exercise: $2.77Exp: 2031-06-24Common Stock (2,083 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-05-1118,3320 total
    Exercise: $10.60Exp: 2032-02-09Common Stock (18,332 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-05-11+18,33218,332 total
    Exercise: $2.77Exp: 2032-02-09Common Stock (18,332 underlying)
Footnotes (5)
  • [F1]The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
  • [F2]Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
  • [F3]On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
  • [F4]The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
  • [F5]On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022, was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.

Issuer

Unity Biotechnology, Inc.

CIK 0001463361

Entity typeother

Related Parties

1
  • filerCIK 0001850065

Filing Metadata

Form type
4
Filed
May 11, 8:00 PM ET
Accepted
May 12, 8:04 PM ET
Size
16.1 KB